Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market || keyplayers


Non-alcoholic steatohepatitis (NASH) is a type of NAFLD. NASH is the liver damage and inflammation caused by the buildup of fat in the liver. It is part of a group of conditions called non-alcoholic fatty liver disease (NAFLD). Non-alcoholic steatohepatitis (NASH), a destructive form of non-alcoholic fatty liver disease (NAFLD), often progress to more severe disorders, such as hepatocellular carcinoma and cirrhosis. Therefore, it has been estimated that NASH may even surpass the hepatitis C virus infection, becoming the major cause of liver transplantation, worldwide, in the coming decade. However, there are still no FDA-approved therapies for this disorder at present, and there is a need to discover appropriate therapeutic targets. The increasing patient population that lacks available specific treatments creates a huge opportunity for the overall market. Several manufacturers are currently developing drugs for the treatment of NASH, and around 90-100 drugs are in the pipeline, at various stages of development, across the globe.

Drivers and Restraints:

Increase in NASH-affected population globally is the major factor driving growth of the global non-alcoholic steatohepatitis (NASH) therapeutics and diagnostics market. According to the NIH data in 2016, NAFLD was one of the most common causes of liver damage in the U.S. Most cases of NAFLD were observed to be those of simple fatty liver. Only a small number of people, who were suffering from NAFLD, were identified with NASH. Therefore, according to the estimates, about 20% of people, who suffered from NAFLD, were identified with NASH. Additionally, NAFLD is more common in people suffering from certain health conditions, including obesity and related conditions, such as type-2 diabetes. In addition, surge in the prevalence of NASH and launch of pipeline drugs is expected to boost growth of the global market during the forecast period. Moreover, surge in prevalence of diabetes & obesity and improvement in awareness of NASH in developing region is projected to supplement the market growth during the forecast period. However, poor diagnosis of the disease and lack of ideal diagnostic techniques are projected to hamper the target market growth over the forecast period.

Request free sample:-

Global Non-alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market, By Product:

  • Therapeutics
  • Elafibranor
  • Ocaliva
  • Selonsertib
  • Cenicriviroc
  • Emricasan
  • Other Therapeutics
  • Diagnostics
  • Imaging Techniques
  • Diagnostic Tests
  • Biopsy

Company Profile:

      • Novartis AG¬†*
        • Company Overview
        • Product Portfolio
        • Key Highlights
        • Financial Performance
  • Allergan PLC
  • Madrigal Pharmaceuticals
  • Galmed Pharmaceuticals
  • Intercept Pharmaceuticals Inc.
  • Gilead Sciences Inc.
  • Novo Nordisk A/S
  • Zydus Cadila
  • Genfit SA
  • Merck & Co.
Back to top button